Skip to main content
. 2018 Sep 24;9(10):986. doi: 10.1038/s41419-018-1040-9

Fig. 6. ABT-263 sensitizes NSCLCs to treatment in orthotopic lung tumor models.

Fig. 6

a Athymic nude mice with luciferase-expressing Calu-6 KO tumors were treated with the vehicle control or ABT-263, and tumor growth was monitored with an IVIS imaging system. Representative images from five mice per group are shown. b Survival curves of mice with Calu-6 KO tumor after treatment with the vehicle control or ABT-263. Statistical analysis was performed with the Gehan-Breslow-Wilcox test. c Representative TUNEL staining images of Calu-6 KO tumors in the vehicle control and ABT-263 treatment groups. d Athymic nude mice with A549 tumors were treated with the indicated agents and imaged for tumor growth using an IVIS imaging system. Representative images from five mice per group were shown. e Survival curves of mice with A549 tumors following different treatments. Statistical analysis was performed with the Gehan-Breslow-Wilcox test (*P < 0.05, **P < 0.01). f Representative TUNEL staining results of A549 tumor from each treatment group